
PLx Pharma PLXP
Quartalsbericht 2022-Q3
hinzugefügt 10.11.2022
PLx Pharma Zahlungsmittel 2011-2026 | PLXP
Zahlungsmittel Jährlich PLx Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 69.4 M | 22.4 M | 14 M | 14.3 M | 24.4 M | 59.3 K | 5.23 M | 27 M | 3.86 M | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 69.4 M | 59.3 K | 20.1 M |
Zahlungsmittel Vierteljährlich PLx Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 25.8 M | 35.7 M | 52.5 M | 69.4 M | 82.6 M | 80.2 M | 84.4 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 14 M | 14 M | 14 M | 14 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 24.4 M | 24.4 M | 24.4 M | 24.4 M | 59.3 K | 59.3 K | 59.3 K | 16.7 M | 91.7 K | 5.23 M | 5.23 M | 5.23 M | 27 M | 27 M | 27 M | 27 M | 3.86 M | 3.86 M | 3.86 M | 3.86 M | 1.46 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 84.4 M | 59.3 K | 22.2 M |
Zahlungsmittel anderer Aktien in der Arzneimittelhersteller
| Name | Zahlungsmittel | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
37.2 M | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
8.86 M | - | 7.5 % | $ 6.35 M | ||
|
Catalent
CTLT
|
289 M | - | - | $ 11.5 B | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
1.08 M | - | 0.86 % | $ 117 M | ||
|
DURECT Corporation
DRRX
|
28.4 M | - | - | $ 50.1 M | ||
|
Endo International plc
ENDP
|
778 M | - | - | $ 28.9 M | ||
|
Agile Therapeutics
AGRX
|
2.56 M | - | 10.11 % | $ 58.2 M | ||
|
Canopy Growth Corporation
CGC
|
114 M | $ 1.1 | 2.84 % | $ 118 M | ||
|
Evoke Pharma
EVOK
|
4.74 M | - | - | $ 36.6 M | ||
|
Alimera Sciences
ALIM
|
12.1 M | - | - | $ 142 M | ||
|
Evolus
EOLS
|
53.8 M | $ 5.68 | 37.53 % | $ 366 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
51.4 M | - | - | $ 2.06 B | ||
|
Jupiter Wellness
JUPW
|
349 K | - | - | $ 33.6 M | ||
|
China Pharma Holdings
CPHI
|
600 K | $ 0.59 | 6.08 % | $ 10.3 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
18 M | $ 3.81 | -16.81 % | $ 53.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
956 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
83.2 M | - | 2.45 % | $ 38.1 M | ||
|
Harrow Health
HROW
|
72.9 M | $ 40.02 | 3.65 % | $ 1.47 B | ||
|
Neoleukin Therapeutics
NLTX
|
148 M | - | - | $ 193 M | ||
|
Aurora Cannabis
ACB
|
138 M | $ 3.65 | 4.89 % | $ 86.3 M | ||
|
Athenex
ATNX
|
30.4 M | - | -23.39 % | $ 1.76 M | ||
|
Emergent BioSolutions
EBS
|
112 M | $ 8.95 | 0.39 % | $ 458 M | ||
|
ProPhase Labs
PRPH
|
9.11 M | - | - | $ 5.07 M | ||
|
Assertio Holdings
ASRT
|
73.4 M | $ 12.19 | 2.48 % | $ 866 M | ||
|
Radius Health
RDUS
|
112 M | - | - | $ 1.42 B | ||
|
Bausch Health Companies
BHC
|
947 M | $ 5.67 | -0.87 % | $ 2.07 B | ||
|
Lannett Company
LCI
|
87.9 M | - | 1.15 % | $ 7.11 M | ||
|
Eagle Pharmaceuticals
EGRX
|
55.3 M | - | -39.89 % | $ 27.7 M | ||
|
Organogenesis Holdings
ORGO
|
136 M | $ 2.87 | 0.01 % | $ 378 M | ||
|
OrganiGram Holdings
OGI
|
24.6 M | $ 1.4 | 2.19 % | $ 402 M | ||
|
Rockwell Medical
RMTI
|
8.98 M | $ 0.91 | 1.03 % | $ 21.2 M | ||
|
Perrigo Company plc
PRGO
|
532 M | $ 11.71 | 2.81 % | $ 1.62 B | ||
|
Sundial Growers
SNDL
|
218 M | $ 1.55 | 1.21 % | $ 3.37 M | ||
|
TherapeuticsMD
TXMD
|
4.33 M | $ 2.25 | 1.35 % | $ 23.5 M | ||
|
Veru
VERU
|
24.9 M | $ 2.53 | 0.4 % | $ 341 M | ||
|
Viatris
VTRS
|
992 M | $ 14.74 | -1.04 % | $ 17.7 B | ||
|
Pacira BioSciences
PCRX
|
277 M | $ 22.92 | 3.69 % | $ 1.06 B | ||
|
PetIQ
PETQ
|
116 M | - | 1.64 % | $ 400 M | ||
|
OptiNose
OPTN
|
73.7 M | - | - | $ 1.08 B | ||
|
Recro Pharma
REPH
|
8.1 M | - | -4.76 % | $ 65.3 M | ||
|
Relmada Therapeutics
RLMD
|
4.09 M | $ 4.79 | 2.57 % | $ 144 M | ||
|
cbdMD
YCBD
|
2.45 M | $ 0.75 | -2.76 % | $ 3.23 M | ||
|
SCYNEXIS
SCYX
|
34 M | $ 0.76 | 1.22 % | $ 36.4 M | ||
|
Solid Biosciences
SLDB
|
80.2 M | $ 6.14 | 3.02 % | $ 251 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
5.37 M | $ 2.74 | -0.36 % | $ 3.4 M | ||
|
Tricida
TCDA
|
21.1 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
207 M | $ 7.33 | -0.48 % | $ 4.53 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
50.6 M | - | - | $ 55.5 M |